Please see these FDA announcements regarding ranitidine removal from the market. As these are products included in some of our institutional order sets, we will be required to do a system wide removal. If an alternative to ranitidine is needed, please contact Janet Reynolds (jreynolds@umc.edu), and she will coordinate with the Institutional Order Set Committee so the changes can be made.

A question has been added to the COVID-19 order to indicate the patient is asymptomatic at the time of testing.

The ambulatory Depression Screening will now present the entire PHQ-9 PHQ-A to be asked to the patient to screen for depression. The sidebar will present different options based on the patient's responses to the Depression Screening. If warranted, the screening for risk of suicide, using the Columbia Suicide Severity Rating Scale, will cascade at the bottom based on the results of the PHQ 9/A. Any additional questions that appear based on patient responses should be answered. In addition, the Quality Measures sidebar will now contain tools to help clinicians address depression and suicide risk.